Sun Dingyong, Liu Jia, Wang Qi, Yang Wenjie, Yue Yanchao, Guo Zhiyong, Yang Shimei, Zhu Qian, Wang Zhe
Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.
Xincai Center for Disease Control and Prevention.
Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Jun;36(6):576-9.
To understand the one-year effect of HCV/HIV co-infected patients who had received AIDS second-line antiretroviral treatment after failure virologically, on the first-line therapy.
HCV and HIV antibody positive patients who had experienced virological failure but received at least one-year AIDS first-line treatment, were recruited from May to October 2012 in Xincai, Queshan and Weishi of Henan province. 6-months and 12-months follow-up programs were carried out after the regimen had been changed to AIDS second-line antiretroviral treatment, CD4⁺ T lymphocyte count, HIV-1 virus load and HIV-1 drug resistance were performed.
Eighty-one cases of eligible patients were selected and followed by an amelioration of CD4 median at 6-month and 12-month follow-up period. Data showed that the baseline, 6-months and 12-months CD4 medians were 266 cells/µl, 275 cells/µl and 299 cells/µl (χ² = 8.214, P = 0.009). The ratio of HIV virus load suppression patients at 6-months and 12-months follow-up increased to 46.84% and 50.00%, respectively. Frequencies of HIV drug resistance also decreased at the baseline, 6-months and 12-months, with ratios as 66.67%, 26.58% and 27.63% (χ² = 29.362, P = 0.000), respectively. Ratios of patients that holding NRTI and NNRTI drug resistance appeared coinstantaneous decrease at the baseline, 6-months and 12-months, as 51.85%, 18.99% and 17.11% (χ² = 14.230, P = 0.005). At the baseline, the ratios of patients resisted to 3TC, ABC and FTC were all more than 50%, with AZT, D4T and DDI between 41%-44% while TDF appeared as 33.33%, then all of them declined to 12%-18% at the 6-month and 12-month follow-up periods. 65.43% of the patients resisted to both NVP and EFV but declined to 24%-27% at 6 months and 12 months.
HCV/HIV co-infected patients experienced virological failure of AIDS first-line therapy were ameliorated after changing to use second-line antiretroviral treatment for 6-months, but did not show constant positive effect at the 12-month end point.
了解丙型肝炎病毒（HCV）/人类免疫缺陷病毒（HIV）合并感染患者在一线治疗病毒学失败后接受艾滋病二线抗逆转录病毒治疗的一年疗效。
2012年5月至10月，从河南省新蔡、确山和尉氏招募HCV和HIV抗体阳性且经历过病毒学失败但接受过至少一年艾滋病一线治疗的患者。在治疗方案改为艾滋病二线抗逆转录病毒治疗后进行6个月和12个月的随访，检测CD4⁺T淋巴细胞计数、HIV-1病毒载量和HIV-1耐药性。
选取81例符合条件的患者，随访期间6个月和12个月时CD4中位数有所改善。数据显示，基线、6个月和12个月时CD4中位数分别为266个细胞/微升、275个细胞/微升和299个细胞/微升（χ² = 8.214，P = 0.009）。随访6个月和12个月时HIV病毒载量被抑制患者的比例分别增至46.84%和50.00%。HIV耐药频率在基线、6个月和12个月时也有所下降，比例分别为66.67%、26.58%和27.63%（χ² = 29.362，P = 0.000）。在基线、6个月和12个月时，同时存在核苷类逆转录酶抑制剂（NRTI）和非核苷类逆转录酶抑制剂（NNRTI）耐药的患者比例同步下降，分别为51.85%、18.99%和17.11%（χ² = 14.230，P = 0.005）。基线时，对拉米夫定（3TC）、阿巴卡韦（ABC）和替诺福韦酯（FTC）耐药的患者比例均超过50%，对齐多夫定（AZT）、司他夫定（D4T）和去羟肌苷（DDI）的耐药比例在41%-44%之间，而对替诺福韦（TDF）的耐药比例为33.33%，在6个月和12个月随访时均降至12%-18%。65.43%的患者对奈韦拉平（NVP）和依非韦伦（EFV）均耐药，但在6个月和12个月时降至24%-27%。
HCV/HIV合并感染且艾滋病一线治疗病毒学失败的患者在改用二线抗逆转录病毒治疗6个月后病情有所改善，但在12个月终点时未显示持续的积极效果。
